Assertio Therapeutics is committed to providing responsible solutions to advance patient care in the Companyâs core areas of neurology, orphan and specialty medicines. Assertio currently markets three FDA-approved products and continues to identify, license and develop new products that offer enhanced options for patients that may be underserved by existing therapies. Source
No articles found.
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a biopharmaceutical company focused on ...
Ocular Therapeutix, Inc. (NASDAQ: OCUL) is a bi...
We are a clinical stage, publicly traded specialty pharmaceutical company, focused...
We are a clinical stage, publicly traded specia...
Citius Pharmaceuticals is a specialty pharmaceutical company dedicated to the deve...
Citius Pharmaceuticals is a specialty pharmaceu...
Neurotrope is a clinical-stage biotech company leveraging Bryostatin-1 and its ana...
Neurotrope is a clinical-stage biotech company ...
PDS Biotechnology has a growing pipeline of clinical-stage immunotherapies to trea...
PDS Biotechnology has a growing pipeline of cli...
Ritter Pharmaceuticals, Inc. develops novel therapeutic products that modulate the...
Ritter Pharmaceuticals, Inc. develops novel the...
Anavex utilizes precision genetic medicine to treat severe and devastating neurolo...
Anavex utilizes precision genetic medicine to t...
Join the National Investor Network and get the latest information with your interests in mind.